Bausch & Lomb eyes up VISX's payment and patent rights
This article was originally published in Clinica
Executive Summary
Bausch & Lomb is still not commenting on whether it plans to fall in line with VISX's payment per procedure strategy in the US or to challenge that company's patent position by not passing on fees when its Technolas 217 laser for LASIK procedures is launched at the end of the year. VISX at present claims a $250 fee per use for excimer laser photorefractive surgery procedures carried out in the US that are covered by one or more of its many patents in this area.